Teva Pharmaceutical Industries Ltd. — Director's Dealing 2023

Mar 7, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)
CIK: 0000818686
Period of Report: 2023-03-03

Reporting Person: Hughes Eric A (See "Remarks")

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-03-03	Restricted Share Units	$	A	99601	Acquired		Ordinary Shares (99601)	Direct

Footnotes

F1: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources
and Compensation Committee, the cash value of one ordinary share.

F2: Restricted share units were granted on March 3, 2023, with 24,900 vesting on each of March 3, 2024, March 3, 2025 and March 3, 2026, and 24,901 vesting on March 3, 2027.

F3: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.